Phase 1/2 × Recruiting × Triple Negative Breast Neoplasms × Clear all A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
Phase 1/2 Recruiting
416 enrolled
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
Phase 1/2 Recruiting
60 enrolled
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Phase 1/2 Recruiting
182 enrolled
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Phase 1/2 Recruiting
300 enrolled
PNeoVCA
Phase 1/2 Recruiting
132 enrolled
A Study of Tetrathiomolybdate (TM) Plus Capecitabine
Phase 1/2 Recruiting
204 enrolled
RAINFOL-01
Phase 1/2 Recruiting
764 enrolled
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
Phase 1/2 Recruiting
250 enrolled
SMP-3124LP in Adults With Advanced Solid Tumors
Phase 1/2 Recruiting
120 enrolled
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
Phase 1/2 Recruiting
949 enrolled
Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Neoadjuvant Triple-negative Breast Cancer
Phase 1/2 Recruiting
12 enrolled
SIMONE
Phase 1/2 Recruiting
60 enrolled
ELUCIDATE
Phase 1/2 Recruiting
230 enrolled
A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer
Phase 1/2 Recruiting
220 enrolled
A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer
Phase 1/2 Recruiting
100 enrolled
BetaBart
Phase 1/2 Recruiting
61 enrolled
A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors
Phase 1/2 Recruiting
100 enrolled
Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases
Phase 1/2 Recruiting
31 enrolled
Study of AVZO-021 in Patients With Advanced Solid Tumors
Phase 1/2 Recruiting
430 enrolled
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
Phase 1/2 Recruiting
200 enrolled
Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
Phase 1/2 Recruiting
108 enrolled
Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC)
Phase 1/2 Recruiting
31 enrolled
A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors
Phase 1/2 Recruiting
270 enrolled
Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI
Phase 1/2 Recruiting
126 enrolled
Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers
Phase 1/2 Recruiting
3 enrolled
ModiFY
Phase 1/2 Recruiting
168 enrolled
DENALI-1
Phase 1/2 Recruiting
240 enrolled
Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)
Phase 1/2 Recruiting
63 enrolled
ComPACT
Phase 1/2 Recruiting
51 enrolled
4CAST
Phase 1/2 Recruiting
65 enrolled
CIRCADIAN
Phase 1/2 Recruiting
20 enrolled
Study of LP-184 in Patients With Advanced Solid Tumors
Phase 1/2 Recruiting
175 enrolled
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
Phase 1/2 Recruiting
316 enrolled
BAH249
Phase 1/2 Recruiting
85 enrolled
CTS2190 Phase I /II Clinical Study in Patients
Phase 1/2 Recruiting
224 enrolled
A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer
Phase 1/2 Recruiting
167 enrolled
COMPASS-TNBC
Phase 1/2 Recruiting
50 enrolled
A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies
Phase 1/2 Recruiting
200 enrolled
TILS001
Phase 1/2 Recruiting
20 enrolled
A Study of the Efficacy and Safety of Camrelizumab Plus Radiotherapy for Patients With Early Triple-Negative Breast
Phase 1/2 Recruiting
20 enrolled